Ireland· IE-PA-EU/1/12/794/001
ADCETRIS 50 mg powder for concentrate for solution for infusion
A brentuximab vedotin product containing brentuximab vedotin, registered in Ireland by Takeda Pharma A/S. The same ATC class is registered in 13 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Brentuximab vedotin is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX05 (brentuximab vedotin), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 8 of them publish a price we can compare per daily dose
Brentuximab vedotin · ATC L01FX05
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of brentuximab vedotin costs, country by country.
Normalised to the WHO defined daily dose (6 mg), the median price runs from $10.73 in Finland to $468.90 in Switzerland — a ×44 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Brentuximab vedotin · price per daily dose (6 mg)
USD · FX 28 Sept 2026
- CH Switzerland$468.90
- FI Finland$10.73
The record
At a glance
HPRA (Ireland)- Active substance
- Brentuximab vedotin
- Manufacturer
- Takeda Pharma A/S
- Country
- Ireland (IE)
- ATC code
- L01FX05
- ATC class
- Brentuximab vedotin
- Defined daily dose
- 6 mg, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/12/794/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
535 interactions on record for brentuximab vedotin.
Graded by severity as the source publishes them — 33 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Brentuximab vedotin · interactions on record
535 records
- 33 severe
- 502 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- ClotrimazoleA01AB18moderate
- RolapitantA04AD14moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Brentuximab vedotin in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandADCETRIS2care4 ApS
- SpainADCETRIS 50 mg POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONTakeda Pharma A/S
- United KingdomAdcetris 50mg powder for concentrate for solution for infusion vialsTakeda UK Ltd
- IcelandADCETRISTakeda Pharma A/S
- NorwayAdcetrisTakeda Pharma A/S (1)
- PolandAdcetrisTakeda Pharma A/S
- BelgiumAdcetris 50 mgTakeda Pharma
- SwedenADCETRIS 50 mg Pulver till koncentrat till infusionsvätska, lösningTakeda Pharma A/S
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Adcetris
- Liechtenstein · Adcetris
- Norway · Adcetris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e3a9a5f6-a7f3-48a3-8661-1e7ecf5ba183 GET /v1/drugs/e3a9a5f6-a7f3-48a3-8661-1e7ecf5ba183?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for concentrate for solution for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"L01FX05"
],
"strength": null,
"pa_number": "EU/1/12/794/001",
"substances": [
"Brentuximab vedotin"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "25/10/2012",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about brentuximab vedotin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.